Slide 1: Accelerating Medicines: First Quarter 2021 Financial Results
Accelerating Medicines First Quarter 2021 Financial Results May 6, 2021
Slide 2: Disclaimer
Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. Trademarks and Service Marks The Certara design logo, “Certara,” and our o
Slide 3: Certara at a Glance: A Global Leader in Biosimulation
Certara at a Glance: A Global Leader in Biosimulation Business End-to-End Platform Customers First Quarter Financials Software 20+ Year • Biosimulation 1,650+ History of innovation • Regulatory Submissions Customers across $66.7mm 61 countries 1Q 2021 Revenue • Value Communication 16% YoY Growth Tec
Slide 4: 1Q 2021 Highlights
1Q 2021 Highlights Key Financials • Revenue was $66.7mm in 1Q 2021, representing year-over-year Three Months Ended growth of 16% March 31, 2021 2020 (in millions, except per share data) Revenue $66.7 $57.4 • Reported net income was $1.1mm in 1Q 2021, as compared to Net Income (Loss) $1.1 $1.0 $1.0mm
Slide 5: 1Q 2021 Results - Revenue
1Q 2021 Results - Revenue GAAP Reported Revenue ($Millions) 44.8 37.2 20.3 21.9 1Q 2020 1Q 2021 Software Services The Certara team remained focused on execution in 1Q 2021, delivering strong revenue growth © Copyright 2020 Certara, L.P. All rights reserved. 5
Slide 6: 1Q 2021 Results - Net Bookings
1Q 2021 Results - Net Bookings Reported Net Bookings ($Millions) 60.0 43.0 18.0 21.9 (1) (1) 1Q 2020 1Q 2021 Software Services Bookings are highly correlated with revenue and drive strong visibility (1) Includes software and software implementation and deployment services related to service segment
Slide 7: 1Q 2021 Results – Adjusted EBITDA
1Q 2021 Results – Adjusted EBITDA ($Millions) Adjusted EBITDA(1) ($Millions) 23.9 19.9 1Q 2020 1Q 2021 Adjusted EBITDA Margin(1) 36% 36% Certara delivered consistent profitability on a year-over-year basis (1) See Appendix for a reconciliation net income (loss) to adjusted EBITDA © Copyright 2020 Ce
Slide 8: Annual Expansion of Customer Partnerships
Annual Expansion of Customer Partnerships Our Customer Growth Strategy Land & Expand Cross-Sell Grow Deeper % of Top 300 Customers Purchasing Customers with ACV > $100,000 Customers with ACV > $1M 2+ Solutions 72% 261 67% 53 228 44 2019 2020 2019 2020 2019 2020 © Copyright 2020 Certara, L.P. All rig
Slide 9: Simcyp PBPK Simulator Version 20
Simcyp™ PBPK Simulator Version 20 • Expands use cases of biosimulation with new and enhanced models for maternal health • Automates the assessment of virtual bioequivalence to attain biowaivers Leading mechanistic biosimulation platform used to • Includes newly expanded Simcyp Biologics Simulator pr
Slide 10: FY 2021 Financial Guidance
FY 2021 Financial Guidance This financial guidance was provided as of May 6, 2021, and its inclusion in this presentation should not be construed as continued affirmation of such guidance beyond that date. • Certara expects full year 2021 revenue to be in the range Full Year 2021 of $277mm to $285mm
Slide 11: Appendix
Accelerating Medicines Appendix
Slide 12: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA THREE MONTHS ENDED MARCH 31, (in thousands) 2021 2020 Net loss(a) $1,052 $1,046 Interest expense(a) 3,928 6,858 Interest income(a) (70) (11) (Benefit from) provision for income taxes(a) 527 621 Depreciation and amortization expense(a) 602 553 In
Slide 13: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) THREE MONTHS ENDED MARCH 31, (in thousands, except per share data) 2021 2020 Net income (loss)(a) $1,052 $1,046 Currency gain (loss) (a) 191 (282) Equity-based compensation expense(b) 5,151 538 Acquisition-related expense(c) 1,596 455
Slide 14: Reconciliation of Diluted EPS to Adjusted Diluted EPS
Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share THREE MONTHS ENDED MARCH 31, 2021 2020 Diluted earnings per share(a) $ 0.01 $ 0.01 Currency gain (loss) (a) — — Equity-based compensation expense(b) 0.03 0.01 Acquisition-related expense(c) 0.01 — Transaction related
Slide 15: Notes to Adjusted EBITDA Reconciliation
Notes to Adjusted EBITDA Reconciliation (a) Represents amounts as determined under GAAP. (b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of o